A Phase 2 interventional study of Hemin for injection and Placebo in Acute Intermittent Porphyria, Hereditary Coproporphyria and Variegate Porphyria, sponsored by The University of Texas Medical Branch, Galveston. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by The University of Texas Medical Branch, Galveston · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Porphyria, Acute Intermittent with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Porphyria, Acute Intermittent · United States.
Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, this one is one of 2 that started in 2015, is one of 2 in phase 2, and was the 6th registered.
21 studies on the registry are indexed under Porphyria, Acute Intermittent; 3 are open to participants now.
Browse Porphyria, Acute Intermittent studies →2 of the 12 studies in Porphyria, Acute Intermittent with a site in United States are open now. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
The American Porphyrias Expert Collaborative · Sites in United States
Ages 1 min+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Porphyria, Acute Intermittent studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 2
First in 2003; this study’s year is marked. 2 started in 2015.
This study's enrollment of 13 is below the median of 20 across 11 interventional studies indexed under Porphyria, Acute Intermittent.
Median enrollment 28 across the 6 interventional studies, 149 across the 6 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 7 most frequent:
The University of Texas Medical Branch, Galveston is the lead sponsor of 257 studies on the registry; 36 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 26 (81%) have results posted.
The University of Texas Medical Branch, Galveston has 3 studies filed under Porphyria, Acute Intermittent — fewer than ten, so there is no comparison to draw.
1 of the studies in Porphyria, Acute Intermittent with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02935400The University of Texas Medical Branch, GalvestonAcute Porphyria Biomarkers for Disease Activity | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if Panhematin is safe and effective for prevention of acute attacks of porphyria.
The study aims to provide high quality evidence for the use on hemin for prevention of acute attacks of porphyria. High quality studies have not been done previously for treating or preventing acute attacks with hemin. The lack of strong evidence for efficacy of hemin for treatment and prevention of attacks limits its availability for patients with acute porphyrias. Funding source: FDA Office of Orphan Product Development (FDA OOPD) FD-R-03720
This is a double-blind, randomized, placebo-controlled, parallel group trial investigating the efficacy and safety of Panhematin™ for preventing acute attacks in at least 20 subjects with well-documented acute porphyria (acute intermittent porphyria, hereditary coproporphyria or variegate porphyria). Subjects will (1.) have had frequent attacks in the past, with symptoms such as abdominal, back and/or limb pain and diagnosed after exclusion of other causes, and (2.) be on hemin prophylaxis for prevention of frequent attacks. It is expected that they will have had 6 or more attacks in one year before starting hemin prophylaxis. This would be considered justification for a preventive regimen of hemin on clinical grounds. Double blind Panhematin™ or placebo will be given. The number of doses will correspond to the number of doses that a subject receives in approximately one week for their prophylactic regimen. An interim analysis will be carried out after completion of 10 subjects to assess progress and possibly adjust the sample size. The trial consists of the following visits:
Any attacks that occur during the study will be treated according to standard of care, which may include Panhematin™, either at the study site or at a subject's usual treatment location.
It is intended that 20 subjects will complete treatment with blinded treatment and at least 4 weeks of follow up. A completed subject is one who meets all entrance criteria, has no exclusion criteria and completes the single dosing and at least one week of follow up, or is withdrawn because of an adverse event.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double blind doses of Panhematin 4 mg/kg body weight reconstituted with 25% human albumin and infused over at least one hour.
Biological: Hemin for injection
A double blind dose of saline.
Other: Placebo
Panhematin 4 mg/kg body weight reconstituted with 25% human albumin infused intravenously over at least 1 hour.
Also known as: Hematin
Saline infusion
Number of Participants Experiencing Acute Attacks of Porphyria After Treatment
Participants were interviewed weekly by telephone to record the number of acute porphyria attacks after initial treatment with Panhematin or placebo.
Time frame: 1-4 weeks
Number of Participants With Treatment-Related Serious Adverse Events
The number of participants who experience treatment-related serious adverse events (SAEs) as assessed and graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Time frame: 1-4 weeks
Effects on Levels of Porphobilinogen
To evaluate the biochemical effects of Panhematin™ in patients treated with Panhematin™ to prevent attacks of acute porphyria by measuring urinary porphobilinogen and serum porphobilinogen. This will determine whether biochemical measurements are predictive of efficacy in preventing an attack.
Time frame: 1-4 weeks
Effects of Age
To evaluate effects of age, as an example of clinical features, on response to preventive administration of Panhematin™.
Time frame: 1-4 weeks
Effects of the Nature of the Porphobilinogen Deaminase (PBGD) Mutation
To evaluate effects of the nature or the PBGD mutation on response to preventive Panhematin™
Time frame: 1-4 weeks
Frequency of Injection Site Complications
To evaluate the use of Panhematin™ reconstituted with 25% human albumin in patients treated to prevent acute attacks of porphyria in terms of the frequency of injection site complications, which may include thrombosis or inflammation.
Time frame: 1-4 weeks
| Milestone | Hemin for Injection | Placebo |
|---|---|---|
| Started | 7 | 6 |
| Completed | 7 | 6 |
| Not completed | 0 | 0 |
Participants were interviewed weekly by telephone to record the number of acute porphyria attacks after initial treatment with Panhematin or placebo.
| Participants | Hemin for Injection | Placebo |
|---|---|---|
| Number of Participants Experiencing Acute Attacks of Porphyria After Treatment | 1 | 5 |
The number of participants who experience treatment-related serious adverse events (SAEs) as assessed and graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
| Participants | Hemin for Injection | Placebo |
|---|---|---|
| Number of Participants With Treatment-Related Serious Adverse Events | 0 | 0 |
To evaluate the biochemical effects of Panhematin™ in patients treated with Panhematin™ to prevent attacks of acute porphyria by measuring urinary porphobilinogen and serum porphobilinogen. This will determine whether biochemical measurements are predictive of efficacy in preventing an attack.
Results for this outcome have not been posted.
To evaluate effects of age, as an example of clinical features, on response to preventive administration of Panhematin™.
Results for this outcome have not been posted.
To evaluate effects of the nature or the PBGD mutation on response to preventive Panhematin™
Results for this outcome have not been posted.
To evaluate the use of Panhematin™ reconstituted with 25% human albumin in patients treated to prevent acute attacks of porphyria in terms of the frequency of injection site complications, which may include thrombosis or inflammation.
Results for this outcome have not been posted.
Collected over 1-4 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hemin for Injection | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
| Placebo | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Age, Categorical(Participants) | Hemin for Injection | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 6 | 13 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Hemin for Injection | Placebo | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Hemin for Injection | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 7 | 6 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Hemin for Injection | Placebo | Total |
|---|---|---|---|
| United States | 7 | 6 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Dec 2023, 97 months.
Results were first posted in Jan 2026, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hemin
Porphyria, Acute Intermittent →
The University of Texas Medical Branch, Galveston →